Search

According to news reporting out of Beijing, People's Republic of China, by NewsRx editors, research stated, "Several prognostic biomarkers have been validated for acute myeloid leukemia (AML), a heterogeneous hematopoietic malignancy. Keywords: Acute Myeloid Leukemia; Cancer; Health and Medicine; Hematology; Leukemia; Myeloid Leukemia; Oncology; Risk and Prevention EN Acute Myeloid Leukemia Cancer Health and Medicine Hematology Leukemia Myeloid Leukemia Oncology Risk and Prevention 396 396 1 08/21/23 20230821 NES 230821 2023 AUG 25 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Research findings on acute myeloid leukemia are discussed in a new report. [Extracted from the article]

Researchers from the First Affiliated Hospital of Wenzhou Medical University conducted a study on acute myeloid leukemia (AML) patients treated with 5-Azacytidine (AZA) and Venetoclax (VEN). They found that miR-182 promoter hypermethylation predicted better outcomes for AML patients receiving this treatment. The study analyzed complete remission rates, overall survival, and leukemia-free survival in relation to miR-182 promoter methylation levels. The research suggests that miR-182 promoter methylation could serve as a predictive biomarker for AML patients undergoing AZA + VEN treatment. [Extracted from the article]

Researchers from Peking University in Beijing, China, conducted a study on patients with lysine methyltransferase 2a (KMT2A)-rearranged acute myeloid leukemia (AML) before undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study found that molecular measurable residual disease (MRD) status before transplantation independently predicted overall survival, leukemia-free survival, relapse risk, and nonrelapse mortality in adult patients with KMT2A-r AML. The presence of KMT2A-r MRD was associated with inferior outcomes, and the study suggests considering donor lymphocyte infusion or posttransplantation maintenance therapies for patients with detectable molecular MRD. [Extracted from the article]

Researchers from Peking University Institute of Hematology conducted a study on acute myeloid leukemia with normal cytogenetics and NPM1 mutations, focusing on the impact of mutation topography on outcomes. The study involved 150 subjects and identified several factors, such as MRD test results and specific mutations, that were independently correlated with relapse and leukemia-free survival. The research concluded by highlighting the importance of identifying co-variates associated with outcomes in NPM1-mutated CN-AML subjects. [Extracted from the article]

A report from Astellas Pharma Inc. discusses the impact of different characteristics on clinical outcomes and treatment patterns for adults with FLT3-ITDmut+ Acute Myeloid Leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT). The study, which included 3,147 eligible patients, found that patients in first complete remission (CR1) had better overall survival (OS) and leukemia-free survival (LFS) compared to those in second or greater complete remission (>= CR2) or relapsed/refractory (R/R) status. The research also identified additional factors that may impact clinical outcomes and inform clinical decision-making. Maintenance therapy usage after alloHCT increased from 2014 to 2019, primarily due to increased FLT3 inhibitor use. [Extracted from the article]

Researchers from Harbin Medical University have published a study on the use of CD19 chimeric antigen receptor-T (CAR-T) cells as a bridging therapy to allogeneic hematopoietic cell transplantation (allo-HSCT) in patients with refractory/relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL). The study found that patients who received CAR-T therapy followed by HSCT had higher overall survival (OS) and leukemia-free survival (LFS) rates compared to those who received CAR-T therapy alone. The results of this clinical trial provide evidence for the safety and efficacy of using CAR-T therapy as a bridging strategy to allo-HSCT in patients with R/R B-ALL. [Extracted from the article]

A recent study conducted by researchers at the Institute for Cancer Research and Treatment (IRCCS) San Raffaele Scientific Institute compared the outcomes of children with acute myeloid leukemia (AML) who underwent hematopoietic stem cell transplantation (HCT) with either a matched unrelated donor (MUD) or a haploidentical donor (haplo). The study found that the risk of grade III-IV acute graft-versus-host disease (aGvHD) was significantly higher in the haplo group. However, there were no significant differences in overall survival, leukemia-free survival, relapse, non-relapse mortality, and graft-versus-host free-relapse free survival between the two groups. The researchers concluded that haplo-HCT with post-transplant cyclophosphamide (PT-CY) is a suitable option for transplanting children with AML who lack a matched related donor. [Extracted from the article]

Researchers from Clinica Ruiz in Puebla, Mexico, conducted a study on treating Acute Promyelocytic Leukemia (APL) patients as outpatients. The study involved 17 patients who were treated with ATRA, prednisone, and adriamycin on an outpatient basis, with successful completion of treatment in 15 cases. Molecular remission was achieved in 16 patients, and the 12-month leukemia-free survival rate was 94%. The research concluded that APL can be effectively treated entirely on an outpatient basis, particularly beneficial in resource-limited settings. [Extracted from the article]

A recent report discusses research on chronic myelomonocytic leukemia (CMML) and its association with dysmyelopoiesis. The study analyzed 240 CMML patients and found that dysgranulopoiesis and dysmegakaryopoiesis were correlated with certain gene mutations and had a negative impact on overall survival and leukemia-free survival. These dysmyelopoiesis markers were not captured by existing prognostic models and may serve as indicators of poor prognostic molecular profiles. The findings highlight the importance of considering dysmyelopoiesis in the diagnosis and prognosis of CMML. [Extracted from the article]

We aimed to compare 2-year leukemia-free survival (LFS) post-HSCT between patients with AML who received post-HSCT maintenance therapy with AZA and prophylactic DLI and historical control patients who did not receive post-HSCT therapy. In 2018, Phoenix Children's Hospital started using post-HSCT maintenance therapy in patients with AML in attempt to decrease the number of relapses after HSCT." Keywords: Phoenix; State:Arizona; United States; North and Central America; Acute Myelogenous Leukemia; Acute Myeloid Leukemia; Antineoplastics; Aza Compounds; Azacitidine; Azacitidine Therapy; Blood Cells; Cancer; Drugs and Therapies; Health and Medicine; Hematology; Hemic and Immune Systems; Hospitals; Immunology; Leukemia; Lymphocytes; Mononuclear Leukocytes; Myelogenous Leukemia; Oncology; Pediatrics; Pharmaceuticals EN Phoenix State:Arizona United States North and Central America Acute Myelogenous Leukemia Acute Myeloid Leukemia Antineoplastics Aza Compounds Azacitidine Azacitidine Therapy Blood Cells Cancer Drugs and Therapies Health and Medicine Hematology Hemic and Immune Systems Hospitals Immunology Leukemia Lymphocytes Mononuclear Leukocytes Myelogenous Leukemia Oncology Pediatrics Pharmaceuticals 2102 2102 1 09/04/23 20230904 NES 230904 2023 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- A new study on Oncology - Acute Myeloid Leukemia is now available. [Extracted from the article]

A recent study conducted at LMU University Hospital in Munich, Germany, compared two different conditioning regimens for patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study found that both regimens, fludarabine-cyclophosphamide-melphalan and fludarabine-cyclophosphamide-treosulfan, were equally effective in terms of overall survival and leukemia-free survival. However, the melphalan-based regimen was associated with a lower risk of relapse but a higher non-relapse mortality rate. The researchers concluded that the treosulfan-based regimen was safe and effective, particularly for patients with advanced disease stages. [Extracted from the article]

A recent study conducted by Harvard University compared the effectiveness of single umbilical cord blood transplantation (sUCBT) and double umbilical cord blood transplantation (dUCBT) in patients with acute leukemia. The study analyzed nine studies involving 3,864 patients and found that dUCBT had a higher risk of acute graft-versus-host disease (GVHD) compared to sUCBT. However, dUCBT had a lower risk of relapse, while sUCBT had better overall survival. The researchers concluded that more research, particularly randomized trials, is needed to determine the optimal use of single and double unit UCBT in acute leukemia patients. [Extracted from the article]

A clinical trial, NCT06401356, has been launched to provide continued access to treatment with pelabresib for patients who previously received pelabresib in a parent study. The study aims to collect safety and efficacy information, monitor the effectiveness of pelabresib in treating the patient's disease, and collect survival follow-up data. Patients who stopped pelabresib treatment for reasons other than participation in this study will not receive further treatment but can enter the study for survival follow-up only. The trial is currently in the recruitment phase and is expected to be completed by June 30, 2024. [Extracted from the article]

A recent study conducted at the Instituto Nacional de Cancerologia examined the prognostic significance of phase angle (PhA) and lean mass index in newly diagnosed acute lymphoblastic leukemia (ALL) patients undergoing intensive chemotherapy. The study found that PhA, a measure of cellular function obtained through bioelectrical impedance analysis, may provide important prognostic information for overall survival (OS) and leukemia-free survival (LFS) in ALL patients. The researchers concluded that PhA is a reliable and potentially interventionable prognostic factor in this population. Further studies should explore the impact of strength training and nutritional supplementation on PhA and patient outcomes. [Extracted from the article]

Drugs and Therapies, Health and Medicine, Kinase Inhibitors, Mastocytosis, Midostaurin Therapy, Pharmaceuticals, Receptor Tyrosine Kinase Inhibitors, Skin Diseases and Conditions, Skin and Connective Tissue Diseases and Conditions, Systemic Mastocytosis Keywords: Drugs and Therapies; Health and Medicine; Kinase Inhibitors; Mastocytosis; Midostaurin Therapy; Pharmaceuticals; Receptor Tyrosine Kinase Inhibitors; Skin Diseases and Conditions; Skin and Connective Tissue Diseases and Conditions; Systemic Mastocytosis EN Drugs and Therapies Health and Medicine Kinase Inhibitors Mastocytosis Midostaurin Therapy Pharmaceuticals Receptor Tyrosine Kinase Inhibitors Skin Diseases and Conditions Skin and Connective Tissue Diseases and Conditions Systemic Mastocytosis 1664 1664 1 06/05/23 20230605 NES 230605 2023 JUN 9 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- A new study on mastocytosis is now available. [Extracted from the article]

Researchers from the University of Utah have made significant contributions to the diagnosis and treatment of Acute Lymphoblastic Leukemia (ALL), a common pediatric malignancy. Their work has led to high complete response rates, long-term remissions, and probable cure in a majority of patients. The research highlights advancements in understanding the causes of ALL, pediatric-inspired treatment trials, L-asparaginase, chimeric antigen receptor T-cell therapy, and aggressive multiagent therapy for high-risk ALL. The study emphasizes the progress made in pediatric hematology/oncology and its positive impact on patient outcomes. [Extracted from the article]

Researchers at University Hospital Carl Gustav Carus in Dresden, Germany, have developed a machine learning pipeline, AIPSS-MDS, to predict the transformation of Myelodysplastic neoplasms (MDS) to Acute Myeloid Leukemia (AML). The pipeline uses clinical, cytogenetic, and molecular data to enhance prediction accuracy, showing promising results in predicting AML transformation at different time points. The study highlights the importance of personalized monitoring strategies to predict disease progression in MDS patients, emphasizing the potential of machine learning models in improving patient outcomes. [Extracted from the article]

The article highlights a study from the University of Alabama Birmingham explores the prognostic value of IDH1 and IDH2 mutations in acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation. Topics discussed include IDH1 and IDH2 mutations, acute myeloid leukemia, allogeneic hematopoietic cell transplantation, and prognostic factors.

This article discusses a clinical trial, NCT06370000, that is testing the feasibility of an oral maintenance strategy for patients with Acute Myeloid Leukemia (AML) who are medically underserved or face disadvantages in certain domains. The trial will evaluate the effectiveness and side effects of maintenance oral azacitidine in these patients. It is a non-randomized pilot study being conducted at a single institution, and it aims to enroll 12 patients by October 31, 2028. The study is open to individuals of all genders aged 18 years and older in the United States. The primary contact for the study is Kristin Lantis, RN, and it is being conducted by Virginia Commonwealth University. [Extracted from the article]

A recent study conducted by researchers at Saitama Medical University International Medical Center in Japan has examined the impact of erythroid dysplasia on the prognosis of patients with aplastic anemia (AA) and myelodysplastic neoplasms (MDS). The study found that erythroid dysplasia should not exclude an AA diagnosis, and that the count of megakaryocytes is important in differentiating between MDS and AA. The research suggests that genetic aberrations are increasingly important in disease classification, but morphological abnormalities continue to play a significant role as a diagnostic tool. [Extracted from the article]

Researchers from the University of Texas MD Anderson Cancer Center have highlighted the role of gamma delta (gd) T cells in acute myeloid leukemia (AML) and their potential as a therapeutic strategy. These gd T cells have the ability to recognize antigens independently of the major histocompatibility complex and bridge the gap between innate and adaptive immunity. Studies in murine models and clinical data in humans have shown that higher reconstitution of gd T cells following hematopoietic stem cell transplantation is associated with improved overall survival, reduced risk of relapse, and enhanced graft-versus-leukemia effect. Clinical trials are exploring the use of unmodified and modified allogeneic cells, bispecific engagers, and monoclonal antibodies to leverage gd T cell biology in AML therapeutics. [Extracted from the article]

A recent study conducted by the Medical College of Wisconsin examined the use of allogeneic hematopoietic cell transplantation (alloHCT) in older patients with acute lymphoblastic leukemia (ALL). The study compared the outcomes of older sibling donors (MSDs) to younger matched unrelated donors (MUDs). The findings showed that younger MUDs conferred a decreased risk of relapse compared to older MSDs. However, younger MUDs were associated with a higher risk of chronic graft-versus-host disease (GVHD) and nonrelapse mortality (NRM). Overall, the study suggests that the use of younger MUDs may be a potential strategy to prevent relapse in older adults with ALL. [Extracted from the article]

A study conducted at the First Affiliated Hospital of Soochow University in Suzhou, China, explored the efficacy and safety of a second CAR-T therapy in patients with refractory/relapsed acute B-cell lymphoblastic leukemia (B-ALL). The study found that the second infusion of tandem CD19/CD22 CAR-T therapy resulted in a better response compared to other infusion strategies. Additionally, bridging allogeneic hematopoietic stem cell transplantation (allo-HSCT) or decitabine (DAC) consolidation after the second CAR-T therapy showed significant survival benefits in patients who achieved complete remission. The study provides valuable insights into potential treatment options for patients with refractory/relapsed B-ALL. [Extracted from the article]

Among those patients, patients receiving related bone marrow transplantation, unrelated bone marrow transplantation, or unrelated cord blood transplantation showed similar survival (5yLFS, 73.2%, 76.3%, and 77.0%, respectively). Keywords: Kyoto; Japan; Asia; Acute Lymphoblastic Leukemia; Bone Marrow; Bone Research; Cancer; Health and Medicine; Hematology; Leukemia; Oncology; Pediatrics; Risk and Prevention EN Kyoto Japan Asia Acute Lymphoblastic Leukemia Bone Marrow Bone Research Cancer Health and Medicine Hematology Leukemia Oncology Pediatrics Risk and Prevention 561 561 1 10/30/23 20231031 NES 231031 2023 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- New research on Oncology - Acute Lymphoblastic Leukemia is the subject of a report. [Extracted from the article]

Keywords: Suzhou; People's Republic of China; Asia; Bone Marrow Diseases and Conditions; Health and Medicine; Hematologic Diseases and Conditions; Hematology; Myelodysplastic Syndromes EN Suzhou People's Republic of China Asia Bone Marrow Diseases and Conditions Health and Medicine Hematologic Diseases and Conditions Hematology Myelodysplastic Syndromes 458 458 1 06/19/23 20230620 NES 230620 2023 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Fresh data on Hematologic Diseases and Conditions - Myelodysplastic Syndromes are presented in a new report. Keywords for this news article include: Suzhou, People's Republic of China, Asia, Bone Marrow Diseases and Conditions, Health and Medicine, Hematologic Diseases and Conditions, Hematology, Myelodysplastic Syndromes, Soochow University. [Extracted from the article]

For more information on this research see: Associations of Minor Histocompatibility Antigens With Outcomes Following Allogeneic Hematopoietic Cell Transplantation. Keywords: Columbus; State:Ohio; United States; North and Central America; Antigens; Biological Factors; Biomedicine; Cancer; Cell Transplantation; Cell Transplants; Health and Medicine; Hematology; Hematopoietic; Histocompatibility Antigens; Immunology; Isoantigens; Leukemia; Minor Histocompatibility Antigens; Oncology; Risk and Prevention; Surface Antigens; Surgery; Transplant Medicine EN Columbus State:Ohio United States North and Central America Antigens Biological Factors Biomedicine Cancer Cell Transplantation Cell Transplants Health and Medicine Hematology Hematopoietic Histocompatibility Antigens Immunology Isoantigens Leukemia Minor Histocompatibility Antigens Oncology Risk and Prevention Surface Antigens Surgery Transplant Medicine 410 410 1 05/22/23 20230522 NES 230522 2023 MAY 22 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators publish new report on Oncology - Leukemia. [Extracted from the article]

Keywords: Cancer; Chronic Myelomonocytic Leukemia; Health and Medicine; Hematology; Leukemia; Myelomonocytic Leukemia; Oncology EN Cancer Chronic Myelomonocytic Leukemia Health and Medicine Hematology Leukemia Myelomonocytic Leukemia Oncology 580 580 1 05/02/23 20230505 NES 230505 2023 MAY 5 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Data detailed on chronic myelomonocytic leukemia have been presented. Cancer, Chronic Myelomonocytic Leukemia, Health and Medicine, Hematology, Leukemia, Myelomonocytic Leukemia, Oncology. [Extracted from the article]

Bone Marrow Diseases and Conditions, Health and Medicine, Hematologic Diseases and Conditions, Hematology, Myelodysplastic Syndromes, Risk and Prevention According to news reporting out of Milan, Italy, by NewsRx editors, research stated, "Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Keywords: Bone Marrow Diseases and Conditions; Health and Medicine; Hematologic Diseases and Conditions; Hematology; Myelodysplastic Syndromes; Risk and Prevention EN Bone Marrow Diseases and Conditions Health and Medicine Hematologic Diseases and Conditions Hematology Myelodysplastic Syndromes Risk and Prevention 300 300 1 04/03/23 20230403 NES 230403 2023 APR 6 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators publish new report on myelodysplastic syndromes. [Extracted from the article]

For more information on this research see: GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT. Keywords: Acute Myeloid Leukemia; Cancer; Graft-Versus-Host Disease; Health and Medicine; Hematology; Immune System Diseases and Conditions; Leukemia; Oncology EN Acute Myeloid Leukemia Cancer Graft-Versus-Host Disease Health and Medicine Hematology Immune System Diseases and Conditions Leukemia Oncology 2023 MAR 6 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Researchers detail new data in acute myeloid leukemia. [Extracted from the article]

For more information on this research see: Chidamide-based 3-drug combination regimen reverses molecular relapse post transplantation in AML1-ETO-positive acute myeloid leukemia. Keywords: Acute Myeloid Leukemia; Cancer; Health and Medicine; Hematology; Leukemia; Myeloid Leukemia; Oncology EN Acute Myeloid Leukemia Cancer Health and Medicine Hematology Leukemia Myeloid Leukemia Oncology 2023 FEB 3 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators publish new report on acute myeloid leukemia. [Extracted from the article]